News & Press
Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau
An article about our tuberculosis (TB) vaccine has been published in the “Frankfurter Rundschau”. For more info click here.
Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows
A clinical trial in South Africa has now shown that the new vaccine candidate VPM1002, developed by Max Planck researcher Stefan H.E. Kaufmann and his team, is equally safe for newborns with and without HIV exposure and has fewer side effects compared to BCG. Please click here to read the publication.
Milestone achieved: end of recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.
Career
Zur Verstärkung unseres Teams im Bereich Finanzen suchen wir in Vollzeit zum nächstmöglichen Zeitpunkt einen: MANAGER FINANCE & CONTROLLING. Mehr dazu hier!
To support our team of Project Managers responsible for company and client projects we are looking for a PROJECT MANAGER to join our team at the earliest opportunity (full time employment). Read more!
To support our Quality Assurance Team we are looking for a QUALITY ASSURANCE MANAGER or ASSISTANT QUALITY ASSURANCE to join our team at the earliest opportunity (full time employment). Read more!